Fentanyl dose estimate emerges for remimazolam intubation in adults
A prospective sequential study has put a numeric boundary around a familiar anesthetic problem: how much fentanyl is needed to blunt the sympathetic surge that can follow tracheal intubation when induction is performed with remimazolam. In this adult elective surgery cohort, investigators used Dixon’s up-and-down method to estimate the dose associated with hemodynamic stability during bolus remimazolam induction. The full-sequence centered isotonic regression estimate of the ED50 was 2.85 µg/kg, with a 90% confidence interval of 2.241 to 3.313.
The finding is narrowly defined, but it is clinically relevant. Remimazolam may preserve hemodynamic stability better than some other induction agents, yet it does not provide analgesia, leaving intubation-associated stimulation unopposed unless another agent is added. In this protocol, fentanyl was the adjunct chosen to blunt that response, and stability was defined with a strict physiologic threshold: mean blood pressure and heart rate had to remain within 20% of baseline for 2 minutes after intubation.
How the dose-finding design defined the answer
The study followed a sequential dose-finding structure rather than a broad comparative trial. Adults undergoing elective surgery received bolus remimazolam 0.2 mg/kg, with fentanyl doses adjusted through Dixon’s up-and-down method based on the prior participant’s response. That design is built to converge on an effective dose range while minimizing unnecessary exposure to doses that are likely too low or too high for the specific condition being tested.
Thirty-one patients were included in the final analysis. The investigators then used centered isotonic regression across the full sequence to estimate the ED50, a statistical approach that makes use of the entire allocation pattern rather than a simple turning-point estimate. The result was a protocol-specific fentanyl requirement of 2.85 µg/kg for hemodynamic stability during intubation under this remimazolam regimen.
A single number can clarify practice, but it can also mislead if it is stripped from its method.
This estimate does not represent a universal induction dose for all adults, all airway conditions, or all anesthetic plans. It is tied to one sedation strategy, one intubation endpoint, and one prospectively defined stability criterion. The authors explicitly caution against reading it as a routine clinical recommendation.
Hemodynamic stability, not just blood pressure, shaped the endpoint
The trial’s primary endpoint was not simply whether blood pressure fell or rose after laryngoscopy. Instead, the outcome required both mean blood pressure and heart rate to stay within 20% of baseline for the 2-minute post-intubation window. That matters because tracheal intubation can provoke a short, sharp catecholamine-driven response, and even modest instability may matter in vulnerable patients.
The study also went beyond a binary success-or-failure label by examining integrated hemodynamic indices. Average real variability, or ARV, and time in target range, or TTR, were calculated from the hemodynamic data to evaluate the quality of induction across the observed fentanyl dose range. Those measures did not show marked variation across the doses studied, suggesting that within this narrow range the hemodynamic pattern did not change dramatically as fentanyl exposure increased.
This does not erase the value of the dose estimate. It suggests that once a certain threshold is reached, the physiologic profile in this small cohort may be relatively similar across nearby doses, at least by the metrics selected for analysis. In practical terms, the result reinforces how tightly balanced induction can be when a hypnotic is used without intrinsic analgesic protection.
What the estimate can and cannot tell anesthesiologists
The most direct clinical takeaway is restrained: remimazolam bolus induction for intubation appears to require a measurable opioid adjunct if the goal is to preserve hemodynamic stability. The study supplies a data-driven estimate rather than a guess, and that estimate sits near the middle of a tight confidence band. For anesthesiologists, that is useful because it anchors the discussion around a concrete pharmacologic requirement rather than an empirical habit.
Still, the trial leaves several questions open. The sample was small, the design was sequential, and the endpoint was protocol-specific. The ED50 is not the same as the dose needed for every individual patient, nor does it establish the dose needed to achieve a desired response in 95% of patients. A broader trial would be needed to define that higher threshold, and to determine whether patient factors, surgical context, or airway difficulty alter the balance.
The absence of marked change in ARV and TTR across the tested dose range may also reflect the study’s scale and the narrow dosing window rather than a universal pharmacodynamic plateau. Larger prospective work will be needed to determine whether these hemodynamic indices can meaningfully distinguish one induction strategy from another when applied to different patient groups.
A protocol-specific answer, not a routine dose recommendation
The study was approved by the Institutional Review Board of Samsung Changwon Hospital, and written informed consent was obtained from all participants. No funding was received, and the authors declared no competing interests. Those details do not change the physiologic result, but they do frame the report as a focused investigator-initiated dose-finding study rather than a sponsor-driven registration trial.
The sharpest clinical message remains the same: under the conditions tested, fentanyl 2.85 µg/kg was the estimated ED50 associated with hemodynamic stability during tracheal intubation after remimazolam bolus induction in adults. The next step is not to universalize that figure, but to test whether it holds when the airway, the patient, and the operative setting become less controlled.